149
Views
4
CrossRef citations to date
0
Altmetric
Articles

A novel evaluation of optimality for randomized controlled trials

, , , , , & show all
Pages 659-672 | Received 16 Feb 2015, Accepted 22 May 2016, Published online: 21 Jul 2016

References

  • Berry, D. A. (2011). Adaptive clinical trials: The promise and the caution. Journal of Clinical Oncology 29(6):606–609
  • Berry, S., Sanil, A. (2010). FACTSTM Dose finding: single endpoint engine specification. Tessela: Newton, MA.
  • Berry, S. M., Carlin, B. P., Lee, J. J., Muller, P. (2011), Bayesian Adaptive Methods for Clinical Trials. CRC Press: New York.
  • Berry, S. M., Spinelli, W., Littman, G. S., Liang, J. Z., Fardipour, P., Berry, D. A., Lewis, R. L., and Krams, M. (2010). A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug, Clinical Trials 7:121–1
  • Cai, C., Liuc, S., Yuanc, Y. (2014). A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine, 33(23):4017–4028
  • Coad, D., Rosenberger, W. (1999). A comparison of the randomized play-the-winner rule and the triangular test for clinical trials with binary responses. Statistics in Medicine 18:761–769
  • Connor, J. T., Luce, B. R., Broglio, K. R., Ishak, K. J., Mullins, C. D., Vanness, D. J., Fleurence, R., Saunders, E., Davis, B. R. (2013). RE-ADAPT study Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clinical Trials 10:807–827
  • Cooper, W., Seiford, L., Tone, K. (2007). Data Envelopment Analysis: A Comprehensive Text with Modes, Applications, References and DEA-solver Software. London, UK: Kluwer Academic Publishers.
  • Daley, C. M., Greiner, K. A., Nazir, N., Daley, S. M., Solomon, C. L., Braiuca, S. L., Smith, T. E., Choi, W. S. (2010). All nations breath of life: using community-based participatory research to address health disparities in cigarette smoking among American Indians. Ethnicity & Disease 20(4):334–338
  • Espey, D. K., Wu, X. C., Swan, J., Wiggins, C., Jim, M. A., Ward, E., et al. (2007). Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 110(10):2119–2152
  • Gajewski, B. J., Berry, S. M., Quintana, M., Pasnoor, M., Dimachkie, M., Herbelin, L., Barohn, R. (2015). Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. Statistics in Medicine 34(7):1134–1149.
  • Gajewski, B., Simon, S., Carlson, S. (2008). Predicting accrual in clinical trials with Bayesian posterior predictive distributions. Statistics in Medicine 27(13):2328–2340
  • Huang, X. L., Ning, J., Li, Y. S., Estey, E., Issa, J. P., Berry, D. A. (2009). Using short-term response information to facilitate adaptive randomization for survival clinical trials. Statistics in Medicine 28:1680–1689.
  • Inoue, L. Y. T., Thall, P. F., Berry, D. A. (2002). Seamlessly expanding a randomized phase II trial to phase III. Biometrics 58:823–831.
  • Israel, E. E., Schulz, A. J., Parker, E. A. (2005). Methods in Community-Based Participatory Research for Health. San Francisco: Jossey-Bass.
  • Jennison, C., Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. New York: Chapman & Hall/CRS.
  • Jiang, Y., Simon, S., Mayo, M. S., and Gajewski, B. J. (2015). Performance of constant accrual model and alternatives on clinical data and simulation. Statistics in Medicine 34(4):613–629
  • Kelly, P. J., Stallard, N., Todd, S. (2005). An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several. Journal of Biopharmaceutical Statistics 15:641–658.
  • Kim, M. O., Liu, C., Hu, F., Lee, J. J. (2014). Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs. Statistics in Medicine 33(23):4029–4042.
  • Lee, J. J., Chu, C. T. (2012). Bayesian clinical trials in action. Statistics in Medicine, 31(25):2955–2972.
  • Mandelblatt, J. S., Cronin, K. A., Bailey, S., Berry, D. A., Koning, H., Draisma, G., Huang, H., Lee, S. J., Munsell, M., Plevritis, S. K., Ravdin, P., Schechter, C. B., Sigal, B., Stoto, M. A., Stout, N. K., van Ravesteyn, N. T., Venier, J., Zelen, M., Feuer, E. J., for the Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET) (2009). effects of mammography screening under different screening schedules: Model estimates of potential benefits and harms. Annals of Internal Medicine 151:738–747.
  • Okuyemi, K., Cox, L. S., Choi, W. S., Ahluwalia, J. S. (2004). Smoking cessation in US Wthnic Minority Populations, Vanguard Conference: Building Success in Smoking Cessation, San Francisco.
  • Pacheco, C. M., Daley, S. M., Brown, T., Filippi, M., Greiner, K. A., Daley, C. M. (2013). Moving forward: Breaking the cycle of mistrust between American Indians and researchers. American Journal of Public Health 103(12):2152–2159.
  • Redwood, D., Lanier, A. P., Renner, C. (2010). Differences in cigarette and smokeless tobacco use among American Indian and Alaska Native people in Alaska and the Southwest United States. Nicotine and Tobacco Research 12(7):791–796.
  • National Medical Association (2000). Recommendations of the clinical trials consensus panel - National Medical Association. Journal of the National Medical Association 92(10):464–471.
  • van der Wouden, J. C., Blankenstein, A. H., Huibers, M. J., van der Windt, D. A., Stalman, W. A., Verhagen, A. P. (2007). Survey among 78 studies showed that Lasagna’s law holds in Dutch primary care research. Journal of Clinical Epidemiology 60(8):819–824.
  • Wilson, P. W. (2006). FEAR: A Software Package for Frontier Efficiency Analysis with R Retrieved from http://www.clemson.edu/economics/faculty/wilson/software/fear/Paper/fear.pdf.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.